GlassScriptPhysician profile
Connor J Mcvey
NPI 1215415633
$7,117.50
in general payments reported to CMS, 2019-2025
20 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,768 · 2022: $917 · 2023: $950 · 2024: $1,579 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,386 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,386.14 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,291.84 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $858.13 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $830.83 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $743.88 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $720.60 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $626.56 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $378.80 | 2021-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $320.75 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $316.49 | 2021-2024 | Trintellix |
| Corium, LLC | $263.65 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $174.77 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $164.29 | 2021-2022 | |
| Incyte Corporation | $100.00 | 2021 | |
| Supernus Pharmaceuticals, INC. | $92.15 | 2024-2025 | Qelbree |
| Bausch Health US, LLC | $74.86 | 2024-2025 | Aplenzin, Wellbutrin |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $49.01 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $43.43 | 2024-2025 | Xelstrym, Secuado |
| Luye Pharma (USA) LTD. | $31.00 | 2025 | Erzofri Extended-Release |
| Orexo US, INC. | $21.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.06 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Mcvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.